Multidrug-resistant and extensively drug-resistant tuberculosis in the Omsk region: trends and characteristics

Written by Pasechnik O.A., Zimoglyad A.A., Yarusova I.V., Vitriv S.V., Blokh A.I.

  UDK: 616–002.5–036.2(571.13) | Pages: 95–100 | Full text PDF | Open PDF 


Objective. Micobacteria resitant to antituberculosis drugs endanger the fight against tuberculosis worldwide.
Methods. A retrospective epidemiological study was conducted, based on the observation of the epidemic process of tuberculosis infection in 2006–2017 in Omsk region. We used the data of federal statistical surveillance forms, and also bacteriograms of tuberculosis patients.
Results. Against the background of a decrease in the incidence of tuberculosis to 62.2 per 100 thousand of the population, the age structure of newly diagnosed patients was changed: an increase in the proportion of people aged 35–44 from 19.2 to 31.9 %, while reducing the proportion of 18–24 y.o. from 13.8 to 6.1 % and 45–54 y.o. from 21.8 to 13.5 %. The number of patients co-infected with the human immunodeficiency virus (from 1.4 to 22 %) has increased. The incidence of bacterial excretion increased from 39.8 to 56 %. 51.8 % of mycobacterial isolates were characterized by different types of drug resistance. Among newly-detected bacterial invaders, the proportion of patients with multidrug-resistant mycobacteria increased from 24.1 to 30.5 %. The incidence of tuberculosis with extensively drug-resistant tuberculosis was 1.6, and prevalence was 13.6 per 100,000 of population and was characterized by a pronounced upward trend.
Conclusions. Under the circumstances, the regional system of epidemiological surveillance will require new approaches to optimization, taking into account changes in the parameters of the epidemic process.

Links to authors:

O.A. Pasechnik¹, A.A. Zimoglyad², I.V. Yarusova³, S.V. Vitriv³, A.I. Blokh¹
1 Omsk State Medical University (12 Lenina St. Omsk 644099 Russian Federation),
2 Health and Epidemiology Center in the Omsk Region (42a 27 Severnaya St. Omsk 644116 Russian Federation),
3 Clinical Antituberculous Dispensary (2 Tselinnaya St. Omsk 644058 Russian Federation)

1. Nechaeva О.B. Epidemicheskaya situatsiya po VICH-infektsii v Rossii. URL: http://mednet.ru/images/stories/files/ CMT/2016vich.pdf (date of access: 18.04.2018).
2. Sterlikov S., Galkin V., Popova N., [et al.]. Estimated prevalence of tuberculosis with multiple and extensive drug resistance by mathematical modeling in the prisons of the Russian Federation // Scientific-Practical Medical Journal. 2018. No. 1. P. 33–41.
3. Tuberkulez v Rossiyskoy Federatsii 2011 g. Analiticheskiy obzor statisticheskikh pokazateley, ispol'zuyemykh v Rossiyskoy Federatsii i v mire. Moscow, 2013. 280 p.
4. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dyhaniya s mnozhestvennoj i shirokoj lekarstvennoj ustojchivostyu vozbuditelya. URL: http://roftb.ru/netcat_files/doks2015/3final.pdf (date of access: 24.04.2018).
5. Anti-tuberculosis drug resistance in the world: the WHO/ IUATLD global project on anti-tuberculosis drug resistance surveillance 2002–2007. Geneva, Switzerland: World Health Organization, 2008. 120 p.
6. Eker B., Ortmann J., Migliori G.B. [et al]. Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany//Emerging Infectious Diseases. 2008. Vol. 14, No. 11. P. 1700–1706.
7. Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review // Thorax. 2006.Vol. 61. P. 158–163.
8. Gandhi N.R., Nunn P., Dheda K. [et al.]. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis // Lancet. 2010. Vol. 375, No. 9728. P. 1830–1843.
9. Global tuberculosis report; Document 2017 (WHO/HTM/ TB/2004.343) [Internet] Geneva: World Health Organization, 2017. [cited 2018 May 4]. URL: http://apps.who.int/iris/bitstream/ handle/10665/259366/9789241565516-eng.pdf (date of access: 24.04.2018).
10. He X.-C., Tao N.-N., Liu Y. [et al.]. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China // BMC Infect. Dis. 2017. Vol. 17, No. 1. P. 555.
11. Marks S.M., Flood J., Seaworth B. [et al.]. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drugresistant tuberculosis, United States, 2005–2007 // Emerging Infectious Diseases. 2014. Vol.20, No. 5. P. 812–821.
12. Qi Y.-C., Ma M.-J., Li D.-J. [et al.]. Multidrug-resistant and extensively drug-resistant tuberculosis in multi-ethnic region, Xinjiang Uygur Autonomous region, China // PLoS ONE. 2012. Vol. 7, No. 2. P. e32103.
13. Raviglione M. XDR-TB: entering the post-antibiotic era? // Int. J. Tuberc. Lung Dis. 2006. Vol. 10. P. 1185–1187.
14. Systematic screening for active tuberculosis: principles and recommendations: Document no 2013 (WHO/HTM/ TB/2013b04) [Internet] Geneva: World Health Organization; 2013. [cited 2018 May]. URL: http://www.who.int/tb/publications/ Final_TB_Screening_guidelines.pdf (date of access: 24.04.2018).
15. Wright A., Zignol M., Van Deun A. [et al.]. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance // Lancet. 2009. Vol. 373. P. 1861–1873.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.